School of Pharmacy, University of Pittsburgh, 3501 Terrace St., Pittsburgh, PA, 15261, USA.
Department of Critical Care Medicine, Center for Critical Care Nephrology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Drug Saf. 2022 Apr;45(4):389-398. doi: 10.1007/s40264-022-01173-4. Epub 2022 Apr 7.
The approach to evaluating nephrotoxins in studies of drug-associated acute kidney injury varies. Some studies use a list of under ten drugs for evaluation whereas others include over 100 drugs. Drugs are typically assigned a binary classification, nephrotoxic or not nephrotoxic. This oversimplifies the nephrotoxic potential of the drugs under investigation.
This study aimed to assign a nephrotoxin potential for 167 drugs used in the adult critical care setting.
A three-round, international, interdisciplinary, web-based modified-Delphi study was used to evaluate nephrotoxins used in adult critically ill patients. Twenty-four international experienced clinicians were identified through the Acute Disease Quality Initiative group and professional affiliations. Included individuals represented the fields of intensive care, nephrology, and pharmacy. One hundred and fifty-nine medications were identified from the literature, with eight additional medications added after the first round, for a total of 167 medications. The primary outcome was consensus achieved for nephrotoxicity ratings. Scores were evaluated each round to determine if a consensus was met.
Our nephrotoxin potential index rating indicated that 20 drugs were nephrotoxicity probable or probable/definite per consensus. Nephrotoxic potential was assessed based on the standard use of medications in intensive care and the following consensus scores: 0 = no nephrotoxic potential, 1 = possible nephrotoxic potential, 2 = probable nephrotoxic potential, 3 = definite nephrotoxic potential.
The nephrotoxin potential index rating allows for prioritization of targeted drugs with greater nephrotoxic potential for institutional nephrotoxin stewardship programs. Furthermore, the nephrotoxin potential index rating provides homogeneity for research and guidance on detailed assessments by severity for each drug.
在药物相关性急性肾损伤的研究中,评估肾毒物的方法有所不同。一些研究使用不到十种药物的清单进行评估,而另一些研究则包括超过 100 种药物。药物通常被分为肾毒性或非肾毒性两类。这过于简化了所研究药物的肾毒性潜力。
本研究旨在为 167 种在成人重症监护环境中使用的药物分配肾毒物潜力。
采用三轮、国际、跨学科、基于网络的改良 Delphi 研究,评估成人危重病患者使用的肾毒物。通过急性疾病质量倡议组织和专业联系,确定了 24 名具有国际经验的临床医生。入选者代表了重症监护、肾脏病学和药学领域。从文献中确定了 159 种药物,第一轮后又增加了 8 种药物,总共 167 种药物。主要结局是对肾毒性评分达成共识。每轮评估分数以确定是否达成共识。
我们的肾毒物潜力指数评分表明,根据药物在重症监护中的标准使用以及以下共识评分,有 20 种药物具有肾毒性的可能性或可能/确定的肾毒性:0 = 无肾毒性潜力,1 = 可能具有肾毒性潜力,2 = 可能具有肾毒性潜力,3 = 确定具有肾毒性潜力。
肾毒物潜力指数评分可优先考虑具有更高肾毒性潜力的靶向药物,用于机构肾毒物管理计划。此外,肾毒物潜力指数评分可提供研究的同质性,并为每个药物的详细严重程度评估提供指导。